At a glance
- Originator Pfizer
- Mechanism of Action Adenosine A3 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Ischaemic heart disorders
Most Recent Events
- 06 Aug 2009 No development reported - Preclinical for Ischaemic heart disorders in USA (unspecified route)
- 25 Mar 2003 Preclinical trials in Ischaemic heart disorders in USA (unspecified route)